| P50 | author | Edwin David G McIntosh | Q97545388 |
| P2860 | cites work | Chlamydia trachomatis: Protective Adaptive Responses and Prospects for a Vaccine | Q37836880 |
| | Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein | Q37841586 |
| | Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial | Q40280300 |
| | Immune correlates of protection against HIV infection and how to elicit them | Q40359021 |
| | Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy | Q40616829 |
| | Status of vaccine research and development of vaccines for herpes simplex virus | Q40757139 |
| | Cost-Benefit Analysis of a Chlamydia trachomatis Vaccine Program in Adolescent Girls in the United States | Q41989587 |
| | Vaccine development for syphilis. | Q42101765 |
| | National Institute of Allergy and Infectious Diseases workshop report: "Chlamydia vaccines: The way forward". | Q44059220 |
| | Immunity in experimental syphilis. VI. Successful vaccination of rabbits with Treponema pallidum, Nichols strain, attenuated by -irradiation | Q44952549 |
| | Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs | Q45740275 |
| | Herpes simplex virus vaccines--why don't antibodies protect? | Q45748053 |
| | Nonhuman Primate Models and Understanding the Pathogenesis of HIV Infection and AIDS. | Q46243818 |
| | Commentary: Impact of meningococcal group B OMV vaccines, beyond their brief | Q46280467 |
| | Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis | Q47194154 |
| | Impact of HPV vaccination with Gardasil® in Switzerland | Q47257772 |
| | Future of human Chlamydia vaccine: Potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles | Q47643650 |
| | Current status of syphilis vaccine development: need, challenges, prospects | Q22251428 |
| | An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection | Q24646809 |
| | Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors | Q27677104 |
| | Costing of National STI Program Implementation for the Global STI Control Strategy for the Health Sector, 2016-2021. | Q29247953 |
| | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 |
| | Identification of Tp0751 (Pallilysin) as a Treponema pallidum Vascular Adhesin by Heterologous Expression in the Lyme disease Spirochete. | Q29994751 |
| | Increasing HIV testing among hard-to-reach groups: examination of RAPID, a community-based testing service in Queensland, Australia | Q33617718 |
| | Development of replication-competent viral vectors for HIV vaccine delivery | Q33694226 |
| | Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium | Q33769332 |
| | HIV: prevention of mother-to-child transmission. | Q33866493 |
| | The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies | Q34142834 |
| | Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer | Q34344205 |
| | Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies | Q34345929 |
| | Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine | Q35329559 |
| | A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates | Q35441545 |
| | Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model | Q35886518 |
| | VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells | Q36161076 |
| | Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo | Q36414891 |
| | A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigs | Q36564785 |
| | Prevention of SHIV transmission by topical IFN-β treatment | Q37150111 |
| | Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 |
| | Future prospects for new vaccines against sexually transmitted infections | Q37665012 |
| | Status of vaccine research and development of vaccines for Chlamydia trachomatis infection | Q37835105 |
| | Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses. | Q52588293 |
| | Zika Virus Shedding in Semen of Symptomatic Infected Men. | Q52593954 |
| | Syphilis Vaccine Development: Requirements, Challenges and Opportunities. | Q54257879 |
| | An Update on Sexual Transmission of Zika Virus | Q56341896 |
| | Sexual transmission of Zika virus and other flaviviruses: A living systematic review | Q56344087 |
| | Immunogenicity and protective efficacy against Treponema pallidum in New Zealand rabbits immunized with plasmid DNA encoding flagellin | Q58594624 |
| | Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial | Q59357445 |
| | Seventy Years of Vaccine Research - Limitations of the Past and Directions for the Future | Q61805093 |
| | Exploitation of Group B OMV Vaccines Against to Inform the Development and Deployment of Effective Gonorrhea Vaccines | Q64063144 |
| | Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. | Q64889038 |
| | Immunization against AIDS in humans | Q69317829 |
| | Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group | Q78082370 |
| | Biological feasibility and importance of a gonorrhea vaccine for global public health | Q88430058 |
| | FDA launches criminal investigation of unauthorised herpes vaccine trial | Q88446550 |
| | The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae | Q90508168 |
| | Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine | Q91129773 |
| | Schoolteachers' experiences of implementing school-based vaccination programs against human papillomavirus in a Chinese community: a qualitative study | Q91257254 |
| | Non-pathogenic Borrelia burgdorferi expressing Treponema pallidum TprK and Tp0435 antigens as a novel approach to evaluate syphilis vaccine candidates | Q91854984 |
| | Cervical Cytokines Associated With Chlamydia trachomatis Susceptibility and Protection | Q92026859 |
| | Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016 | Q92433030 |
| | Successful application of prime and pull strategy for a therapeutic HSV vaccine | Q92512520 |
| | Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap | Q93055629 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | Zika virus | Q202864 |
| P304 | page(s) | 2515135520923887 | |
| P577 | publication date | 2020-06-27 | |
| P1433 | published in | Therapeutic Advances in Vaccines and Immunotherapy | Q58236120 |
| P1476 | title | Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus | |
| P478 | volume | 8 | |